cholangiocarcinoma (Cancer)
Information
- Disease name
- cholangiocarcinoma
- Disease ID
- DOID:4947
- Description
- "A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells." [url:http\://cancergenome.nih.gov/cancersselected/Cholangiocarcinoma, url:http\://en.wikipedia.org/wiki/Cholangiocarcinoma, url:http\://www.cancer.gov/dictionary?CdrID=335064]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| APC | 5 | 112,737,885 | 112,846,239 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04521686 | Active, not recruiting | Phase 1 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | October 16, 2020 | May 2025 |
| NCT05194735 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | April 4, 2022 | November 30, 2024 |
| NCT04526106 | Active, not recruiting | Phase 1/Phase 2 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | September 2, 2020 | October 2024 |
| NCT04238715 | Active, not recruiting | Phase 2 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion | January 22, 2020 | September 1, 2024 |
| NCT04421820 | Active, not recruiting | Phase 1/Phase 2 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | August 28, 2020 | September 30, 2024 |
| NCT02626312 | Active, not recruiting | Phase 1 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function | February 15, 2016 | April 28, 2026 |
| NCT04913337 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | June 9, 2021 | July 2025 |
| NCT04853017 | Active, not recruiting | Phase 1 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | October 4, 2021 | March 2026 |
| NCT04306367 | Active, not recruiting | Phase 2 | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | April 1, 2020 | December 1, 2023 |
| NCT04233567 | Active, not recruiting | Phase 2 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | January 16, 2020 | December 31, 2023 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT04308174 | Active, not recruiting | Phase 2 | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer | May 20, 2020 | December 30, 2024 |
| NCT02568267 | Active, not recruiting | Phase 2 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | November 19, 2015 | April 1, 2025 |
| NCT05519605 | Active, not recruiting | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD | August 1, 2022 | July 1, 2024 | |
| NCT02232932 | Active, not recruiting | N/A | Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma | March 2014 | September 2024 |
| NCT03693807 | Active, not recruiting | Phase 2 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | October 18, 2018 | September 2024 |
| NCT05451849 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | June 21, 2022 | October 30, 2028 |
| NCT02170090 | Active, not recruiting | Phase 3 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer | April 2014 | April 2024 |
| NCT05432193 | Active, not recruiting | Phase 1 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | July 13, 2022 | December 2026 |
| NCT03907852 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | April 15, 2019 | November 2, 2028 |
| NCT02482454 | Active, not recruiting | Phase 2/Phase 3 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | July 2012 | July 2033 |
| NCT05311618 | Active, not recruiting | Phase 1 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | May 11, 2022 | June 2025 |
| NCT05292859 | Active, not recruiting | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | October 1, 2022 | June 2039 | |
| NCT04383210 | Active, not recruiting | Phase 2 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | September 29, 2020 | March 2025 |
| NCT03414489 | Available | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | |||
| NCT06370013 | Available | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | |||
| NCT04566393 | Available | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | |||
| NCT04100694 | Available | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | |||
| NCT05464706 | Completed | N/A | Study on the Quality of Life (QoL) After Liver Surgery | January 1, 2018 | July 1, 2022 |
| NCT01392274 | Completed | pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture | April 2012 | September 2013 | |
| NCT01438554 | Completed | Phase 1 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | October 2011 | August 2018 |
| NCT05028439 | Completed | N/A | RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | January 1, 2020 | December 30, 2022 |
| NCT01595217 | Completed | N/A | MRCP Diagnoses EHCC Better When Combined DWI | March 2012 | May 2013 |
| NCT04919642 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | December 7, 2021 | February 28, 2024 |
| NCT01673269 | Completed | N/A | Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD | July 2012 | October 2013 |
| NCT01673802 | Completed | Early Phase 1 | The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma | August 2012 | January 2014 |
| NCT04742959 | Completed | Phase 1/Phase 2 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | March 14, 2021 | February 20, 2024 |
| NCT01773655 | Completed | Clinical and Histopathologic Characteristics of BAP1 Mutations | January 2013 | June 30, 2020 | |
| NCT01844245 | Completed | N/A | Endobiliary RFA for Unresectable Malignant Biliary Strictures | May 2013 | July 2019 |
| NCT04676633 | Completed | Phase 1 | Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | March 1, 2021 | January 13, 2023 |
| NCT04656249 | Completed | Phase 2 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer | January 1, 2018 | May 1, 2021 |
| NCT04642664 | Completed | Phase 2 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | December 1, 2018 | January 1, 2021 |
| NCT01900158 | Completed | Phase 1 | A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | May 2013 | February 2019 |
| NCT01912053 | Completed | Phase 2 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma | September 2013 | November 2017 |
| NCT04568512 | Completed | N/A | DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture | January 1, 2016 | December 31, 2019 |
| NCT01926236 | Completed | Phase 3 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers | February 2014 | January 2019 |
| NCT01963325 | Completed | Phase 2 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | August 2013 | December 2017 |
| NCT02000999 | Completed | Diagnosis of Bile Duct Strictures | November 2013 | January 2, 2019 | |
| NCT02027311 | Completed | Phase 4 | Etomidate vs. Midazolam for Sedation During ERCP | April 2013 | August 2013 |
| NCT02052778 | Completed | Phase 1/Phase 2 | A Study of TAS-120 in Patients With Advanced Solid Tumors | July 21, 2014 | May 29, 2021 |
| NCT02073994 | Completed | Phase 1 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | March 1, 2014 | January 4, 2024 |
| NCT02128282 | Completed | Phase 1/Phase 2 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | June 2014 | August 5, 2021 |
| NCT03486678 | Completed | Phase 2 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | February 10, 2018 | November 30, 2020 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03801915 | Completed | Phase 2 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | November 13, 2019 | May 27, 2022 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT03769753 | Completed | Phase 2 | Trial of IRE in Cholangiocarcinoma | December 5, 2018 | August 16, 2021 |
| NCT03613168 | Completed | Phase 2 | Trastuzumab in HER2-positive Biliary Tract Cancer | June 1, 2019 | January 4, 2021 |
| NCT03644173 | Completed | N/A | Personal Resilience Empowerment Program Study | May 30, 2018 | June 14, 2021 |
| NCT03665285 | Completed | Phase 1/Phase 2 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | October 1, 2018 | April 11, 2023 |
| NCT00465023 | Completed | N/A | Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases | June 2003 | January 2017 |
| NCT00660140 | Completed | Phase 2 | Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer | March 2002 | April 2009 |
| NCT06258824 | Completed | MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers | January 1, 2018 | July 27, 2020 | |
| NCT00733200 | Completed | N/A | Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection? | ||
| NCT00779454 | Completed | Phase 2 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | September 2008 | March 2016 |
| NCT00869635 | Completed | Phase 3 | S-1 and Photodynamic Therapy in Cholangiocarcinoma | February 2009 | August 2013 |
| NCT00948935 | Completed | Phase 2 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | April 2009 | September 26, 2014 |
| NCT00955149 | Completed | Phase 1 | Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | August 2009 | April 2013 |
| NCT01007552 | Completed | Phase 2 | A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts | December 2009 | May 2015 |
| NCT01043172 | Completed | Phase 2 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | July 20, 2009 | December 31, 2016 |
| NCT01135732 | Completed | Cytological Evaluation of Biliary Epithelium After Endoscopic Sphincterotomy | October 2006 | ||
| NCT01145248 | Completed | N/A | Comparison of Biliary Forceps Biopsy and Brush Cytology | January 2006 | July 2009 |
| NCT05518071 | Completed | Phase 2 | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 | November 9, 2022 | May 23, 2024 |
| NCT01206049 | Completed | Phase 2 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | September 2010 | March 2016 |
| NCT01213758 | Completed | Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT | June 2010 | April 2016 | |
| NCT01242605 | Completed | Phase 1 | ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer | February 2012 | May 2016 |
| NCT01247337 | Completed | Phase 2 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | February 2, 2011 | February 18, 2016 |
| NCT01253148 | Completed | N/A | Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma | January 2011 | August 2015 |
| NCT01267344 | Completed | Phase 2 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC | December 2010 | May 2015 |
| NCT01290536 | Completed | Phase 2 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | May 2010 | October 2013 |
| NCT03999593 | Completed | Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma | January 2009 | October 2017 | |
| NCT03150615 | Completed | N/A | Enteral Nutrition After Pancreaticoduodenectomy | September 2016 | February 2018 |
| NCT03895970 | Completed | Phase 2 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | April 20, 2019 | August 1, 2021 |
| NCT03178409 | Completed | Combined HCC-MFCCC | January 1, 2004 | May 15, 2017 | |
| NCT03207347 | Completed | Phase 2 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | August 13, 2018 | August 30, 2022 |
| NCT03833661 | Completed | Phase 2 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | March 26, 2019 | September 30, 2022 |
| NCT03219268 | Completed | Phase 1 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | August 18, 2017 | February 8, 2023 |
| NCT03250273 | Completed | Phase 2 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | November 6, 2017 | November 20, 2020 |
| NCT03267966 | Completed | N/A | Margin Status After Pancreaticoduodenectomy for Cancer | March 2013 | June 2019 |
| NCT03278106 | Completed | Phase 2 | TAS-102 in Treating Advanced Biliary Tract Cancers | October 20, 2017 | September 16, 2021 |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT03338062 | Completed | N/A | A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy | June 13, 2017 | September 2, 2019 |
| NCT03339843 | Completed | Phase 2 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib | December 19, 2018 | December 20, 2023 |
| NCT03377179 | Completed | Phase 2 | A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma | March 7, 2018 | June 21, 2022 |
| NCT03438435 | Completed | Phase 1 | Fluorescence QRH-882260 Peptide Imaging in the Bile Duct | April 22, 2019 | August 21, 2020 |
| NCT00350753 | Completed | Phase 2 | Avastin and Tarceva for Upper Gastrointestinal Cancers | June 2006 | June 2009 |
| NCT00350961 | Completed | Phase 1/Phase 2 | Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma | June 2004 | February 2008 |
| NCT03473574 | Completed | Phase 2 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients | May 2, 2018 | March 15, 2022 |
| NCT03829436 | Completed | Phase 1 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | March 20, 2019 | September 7, 2022 |
| NCT00041808 | Completed | Phase 1/Phase 2 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | July 2001 | April 2003 |
| NCT02181634 | Completed | Phase 2 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma | December 9, 2014 | October 1, 2017 |
| NCT02232633 | Completed | Phase 2 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | February 2015 | December 14, 2017 |
| NCT02351765 | Completed | Phase 1 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers | January 2016 | March 2019 |
| NCT04440943 | Completed | Phase 1 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | August 4, 2020 | April 6, 2023 |
| NCT02375880 | Completed | Phase 1 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | June 2015 | July 2018 |
| NCT00168987 | Completed | Phase 4 | Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors | January 2005 | June 2007 |
| NCT04430842 | Completed | Phase 1 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | July 20, 2020 | December 22, 2022 |
| NCT02428855 | Completed | Phase 2 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | April 2015 | February 2018 |
| NCT04385147 | Completed | Advanced Endoscopy During COVID-19 | May 18, 2020 | July 5, 2020 | |
| NCT02456714 | Completed | Phase 2 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma | May 31, 2016 | December 1, 2018 |
| NCT02468076 | Completed | Phase 2 | Radiofrequency Ablation for Biliopancreatic Malignancy | November 2014 | March 2016 |
| NCT02496741 | Completed | Phase 1/Phase 2 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors | November 2015 | November 18, 2019 |
| NCT02520141 | Completed | Phase 2 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | December 29, 2015 | June 29, 2022 |
| NCT04316078 | Completed | N/A | A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies | March 15, 2020 | April 15, 2022 |
| NCT02585856 | Completed | N/A | Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma | February 2013 | August 2018 |
| NCT02592538 | Completed | N/A | Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma | December 2015 | March 2019 |
| NCT02609958 | Completed | Phase 2 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | November 16, 2015 | October 11, 2017 |
| NCT00230347 | Completed | Phase 1 | Evaluation of Stereotactic Radiosurgery For Liver Malignancies | October 2003 | February 2007 |
| NCT02631590 | Completed | Phase 2 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | July 5, 2016 | March 5, 2021 |
| NCT04301999 | Completed | N/A | Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | March 1, 2020 | August 27, 2021 |
| NCT02649712 | Completed | N/A | Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction | January 20, 2016 | October 31, 2018 |
| NCT04256980 | Completed | Phase 2 | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | March 3, 2020 | August 31, 2023 |
| NCT02683538 | Completed | Phase 2 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | November 2011 | July 2014 |
| NCT02730611 | Completed | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma | March 2016 | December 2018 | |
| NCT02762721 | Completed | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | June 6, 2016 | April 6, 2017 | |
| NCT02784795 | Completed | Phase 1 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | November 4, 2016 | February 13, 2020 |
| NCT02821754 | Completed | Phase 2 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | July 5, 2016 | December 31, 2022 |
| NCT02924376 | Completed | Phase 2 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | January 16, 2017 | February 1, 2022 |
| NCT02990481 | Completed | Phase 1 | A Study of TRK-950 in Patients With Advanced Solid Tumors | March 6, 2017 | September 16, 2019 |
| NCT03003065 | Completed | Phase 2 | Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers | March 28, 2014 | August 12, 2023 |
| NCT03027284 | Completed | Phase 1 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | February 3, 2017 | March 17, 2020 |
| NCT03041662 | Completed | Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC) | October 31, 2011 | November 30, 2020 | |
| NCT04137289 | Completed | Phase 1 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | March 11, 2020 | November 27, 2023 |
| NCT03079427 | Completed | Phase 2 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | May 15, 2017 | November 15, 2022 |
| NCT03111732 | Completed | Phase 2 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | June 14, 2017 | November 8, 2021 |
| NCT04059562 | Completed | Phase 2 | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma | October 28, 2021 | January 8, 2024 |
| NCT04572711 | Enrolling by invitation | Prospective Evaluation of Biliary Tissue Sampling With ERCP | September 1, 2020 | May 2026 | |
| NCT04340986 | Not yet recruiting | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma | April 2020 | April 2030 | |
| NCT06175845 | Not yet recruiting | N/A | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma | February 2024 | July 2026 |
| NCT05580328 | Not yet recruiting | N/A | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | December 1, 2022 | October 1, 2024 |
| NCT05653817 | Not yet recruiting | N/A | Advanced or Metastatic Cholangiocarcinoma | January 31, 2023 | January 31, 2026 |
| NCT06358001 | Not yet recruiting | EchoTip AcuCore Post-Market Clinical Study | June 1, 2024 | June 1, 2025 | |
| NCT06434493 | Not yet recruiting | N/A | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma | June 1, 2024 | January 1, 2029 |
| NCT05694845 | Not yet recruiting | Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma | February 2024 | February 2026 | |
| NCT06440018 | Not yet recruiting | INSPIRE: A Multi-Cancer Early Detection Study | June 20, 2024 | February 28, 2025 | |
| NCT05697237 | Not yet recruiting | N/A | Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma | January 2023 | December 2024 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT06416397 | Not yet recruiting | Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy | June 2024 | February 2026 | |
| NCT06438822 | Not yet recruiting | Phase 2 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | May 28, 2024 | November 30, 2026 |
| NCT06369896 | Not yet recruiting | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures | May 5, 2024 | December 25, 2026 | |
| NCT05207735 | Not yet recruiting | Phase 2 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | January 2022 | December 2024 |
| NCT05321992 | Not yet recruiting | N/A | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand | July 1, 2024 | April 1, 2026 |
| NCT06399757 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | May 2024 | May 2027 |
| NCT06441747 | Not yet recruiting | Phase 2 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | August 2024 | August 2028 |
| NCT06355427 | Not yet recruiting | Phase 2/Phase 3 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma | September 1, 2024 | February 1, 2028 |
| NCT04445532 | Recruiting | Hepatobiliary Tumors Tissue Samples Acquisition | October 11, 2020 | June 1, 2025 | |
| NCT01915225 | Recruiting | Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | July 21, 2013 | ||
| NCT02379377 | Recruiting | Phase 1 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | February 15, 2022 | May 31, 2025 |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT02757859 | Recruiting | N/A | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | April 27, 2016 | January 2025 |
| NCT02773485 | Recruiting | Phase 3 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | May 2015 | June 2025 |
| NCT02917759 | Recruiting | Liver and Biliary Tumor Tissue Registry | February 2014 | February 2029 | |
| NCT03445585 | Recruiting | Biobank for Cholestatic Liver Diseases. | January 2017 | January 2050 | |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT03637569 | Recruiting | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | April 1, 2018 | December 31, 2026 | |
| NCT03801083 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | February 19, 2019 | January 31, 2030 |
| NCT03820310 | Recruiting | Phase 2 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | May 1, 2018 | December 2025 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT03924466 | Recruiting | Phase 2 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | April 1, 2019 | December 2024 |
| NCT03991832 | Recruiting | Phase 2 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | December 31, 2019 | March 31, 2025 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04037007 | Recruiting | N/A | Efficacy of Fistulotomy for Biliary Cannulation | July 3, 2019 | December 3, 2022 |
| NCT04068194 | Recruiting | Phase 1/Phase 2 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | April 7, 2020 | December 3, 2024 |
| NCT04145141 | Recruiting | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | July 28, 2021 | December 31, 2025 | |
| NCT04149691 | Recruiting | Phase 1 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | July 19, 2019 | June 2024 |
| NCT04157985 | Recruiting | Phase 3 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | November 15, 2019 | October 2028 |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT04459273 | Recruiting | Phase 1 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | August 27, 2020 | July 1, 2025 |
| NCT04484636 | Recruiting | N/A | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) | October 28, 2020 | July 30, 2024 |
| NCT04504604 | Recruiting | N/A | TCF-001 TRACK (Target Rare Cancer Knowledge) Study | October 1, 2020 | December 2025 |
| NCT04510740 | Recruiting | Liver Cancer Registry Platform | August 9, 2020 | December 2026 | |
| NCT04561453 | Recruiting | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | July 8, 2020 | July 1, 2025 | |
| NCT04565275 | Recruiting | Phase 1/Phase 2 | A Study of ICP-192 in Patients With Advanced Solid Tumors | February 1, 2021 | April 15, 2024 |
| NCT04645160 | Recruiting | Phase 1/Phase 2 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | March 4, 2022 | December 31, 2027 |
| NCT04668976 | Recruiting | Phase 2 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | November 25, 2020 | December 2024 |
| NCT04753996 | Recruiting | Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients | March 8, 2021 | January 2025 | |
| NCT04792463 | Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | March 3, 2015 | July 1, 2026 | |
| NCT04801095 | Recruiting | Phase 1 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | July 14, 2021 | August 8, 2025 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04856761 | Recruiting | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | November 1, 2020 | December 30, 2024 | |
| NCT04871321 | Recruiting | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | April 14, 2021 | December 31, 2024 | |
| NCT04946773 | Recruiting | Deep Liver Phenotyping and Immunology Study | March 12, 2021 | October 31, 2040 | |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05179486 | Recruiting | Molecular Epidemiology of Biliary Tree Cancers | September 25, 2017 | February 2, 2027 | |
| NCT05184400 | Recruiting | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer | January 1, 2015 | December 31, 2030 | |
| NCT05187312 | Recruiting | Registry for Advanced Endoscopy | January 14, 2022 | January 14, 2032 | |
| NCT05194072 | Recruiting | Phase 1 | A Study of SGN-B7H4V in Advanced Solid Tumors | January 12, 2022 | January 31, 2027 |
| NCT05215574 | Recruiting | Phase 1 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | March 31, 2022 | March 2026 |
| NCT05215665 | Recruiting | N/A | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma | January 15, 2022 | January 15, 2026 |
| NCT05253053 | Recruiting | Phase 1/Phase 2 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | April 13, 2022 | December 2024 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT05346484 | Recruiting | Phase 1 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | May 17, 2022 | January 2025 |
| NCT05348811 | Recruiting | Phase 2 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | December 28, 2022 | July 15, 2023 |
| NCT05411133 | Recruiting | Phase 1 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | May 30, 2022 | August 2025 |
| NCT05451043 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | July 5, 2023 | October 1, 2028 |
| NCT05461430 | Recruiting | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | July 15, 2022 | July 2026 | |
| NCT05489250 | Recruiting | The PLATON Network | October 28, 2020 | May 31, 2032 | |
| NCT05497531 | Recruiting | N/A | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | September 7, 2022 | October 2024 |
| NCT05506943 | Recruiting | Phase 2/Phase 3 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | January 9, 2023 | December 2025 |
| NCT05563272 | Recruiting | Phase 2 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | June 6, 2023 | December 29, 2025 |
| NCT05596370 | Recruiting | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer | January 6, 2022 | December 31, 2024 | |
| NCT05600803 | Recruiting | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions | October 30, 2022 | October 30, 2025 | |
| NCT05634694 | Recruiting | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients | November 30, 2022 | December 1, 2024 | |
| NCT05641896 | Recruiting | Phase 2 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers | April 28, 2023 | March 31, 2025 |
| NCT05655949 | Recruiting | Phase 2 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | February 13, 2024 | December 1, 2027 |
| NCT05669430 | Recruiting | Phase 1 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | March 23, 2023 | June 15, 2026 |
| NCT05678218 | Recruiting | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma | September 5, 2022 | February 1, 2026 | |
| NCT05712356 | Recruiting | Phase 2 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | August 24, 2023 | December 2025 |
| NCT05714124 | Recruiting | Liver Embolization Approaches for Tumor Management | May 21, 2021 | December 31, 2031 | |
| NCT05718349 | Recruiting | FGF19 in Obstructive Cholestasis: "Unveil the Signal" | January 1, 2017 | June 1, 2025 | |
| NCT05721963 | Recruiting | Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients | February 1, 2023 | December 31, 2024 | |
| NCT05724563 | Recruiting | Phase 2 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | June 1, 2023 | June 1, 2027 |
| NCT05788484 | Recruiting | Phase 1 | A Study of CDX-585 in Patients With Advanced Malignancies | May 11, 2023 | February 2026 |
| NCT05848739 | Recruiting | Phase 1 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | June 5, 2023 | May 31, 2027 |
| NCT05872867 | Recruiting | Phase 1 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | March 14, 2024 | February 22, 2026 |
| NCT05874414 | Recruiting | Phase 1/Phase 2 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma | August 21, 2023 | October 2026 |
| NCT05876754 | Recruiting | Phase 3 | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma | May 3, 2023 | June 1, 2025 |
| NCT05921552 | Recruiting | N/A | Senior Adult Hepatobiliary Prehab Study | June 14, 2023 | September 2024 |
| NCT05948475 | Recruiting | Phase 3 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | December 20, 2023 | August 2026 |
| NCT05957250 | Recruiting | N/A | [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer | February 3, 2023 | July 1, 2026 |
| NCT05967182 | Recruiting | Phase 2 | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | January 16, 2024 | July 31, 2029 |
| NCT05993429 | Recruiting | Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma | August 14, 2023 | August 1, 2027 | |
| NCT06010862 | Recruiting | Phase 1 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | September 30, 2023 | September 30, 2026 |
| NCT06037980 | Recruiting | Phase 2/Phase 3 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | November 7, 2023 | January 2029 |
| NCT06048133 | Recruiting | Phase 2 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | March 8, 2024 | July 2025 |
| NCT06048289 | Recruiting | Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy | September 14, 2023 | March 31, 2025 | |
| NCT06126406 | Recruiting | Phase 1 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | November 6, 2023 | December 31, 2026 |
| NCT06199895 | Recruiting | Phase 2 | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer | November 28, 2023 | November 2025 |
| NCT06260943 | Recruiting | N/A | Targeted Navigation in Hepatocellular Carcinoma (HCC) | April 15, 2024 | October 31, 2026 |
| NCT06290856 | Recruiting | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy | January 15, 2024 | December 15, 2025 | |
| NCT06302621 | Recruiting | Phase 1 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | July 1, 2024 | December 1, 2025 |
| NCT06304766 | Recruiting | N/A | Open Versus Laparoscopic Ablation of Liver Malignancies | December 15, 2023 | December 2025 |
| NCT06340646 | Recruiting | N/A | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) | October 18, 2022 | January 31, 2027 |
| NCT06341764 | Recruiting | Phase 2 | Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma | September 1, 2023 | September 2025 |
| NCT06342414 | Recruiting | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer | March 15, 2024 | March 15, 2025 | |
| NCT06363123 | Recruiting | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | March 29, 2024 | April 2025 | |
| NCT06369480 | Recruiting | Prognostic Factors for Survival in Patients With Cholangiocarcinoma | February 1, 2024 | August 31, 2024 | |
| NCT06381648 | Recruiting | Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) | April 15, 2023 | June 18, 2026 | |
| NCT01859169 | Suspended | Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma | June 2013 | June 2016 | |
| NCT05124743 | Suspended | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | September 24, 2021 | May 28, 2028 | |
| NCT01855724 | Terminated | Phase 2 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | June 28, 2013 | September 28, 2018 |
| NCT00955721 | Terminated | Phase 1/Phase 2 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | August 2009 | July 2014 |
| NCT00301379 | Terminated | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | August 12, 2005 | June 6, 2023 | |
| NCT02872831 | Terminated | N/A | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | July 2016 | November 2017 |
| NCT00414843 | Terminated | Storage of Bile From Routine Procedures to Study Risk Factors | December 2006 | August 2015 | |
| NCT04989218 | Terminated | Phase 1/Phase 2 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) | January 30, 2023 | May 1, 2024 |
| NCT03211169 | Terminated | N/A | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures | July 29, 2017 | September 1, 2019 |
| NCT02638909 | Terminated | Phase 2 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | December 2015 | March 29, 2018 |
| NCT04304781 | Terminated | Phase 1 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | September 22, 2020 | December 17, 2021 |
| NCT03852836 | Terminated | N/A | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images | February 26, 2019 | September 15, 2021 |
| NCT00975039 | Terminated | Phase 2 | Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | September 2009 | September 2012 |
| NCT03172832 | Terminated | N/A | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors | August 20, 2017 | April 12, 2019 |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT02479178 | Terminated | Phase 2 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck | June 2015 | January 2020 |
| NCT02452970 | Terminated | Phase 2 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy | July 16, 2015 | May 25, 2016 |
| NCT01525069 | Terminated | Phase 1 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | April 3, 2012 | August 2, 2022 |
| NCT00320918 | Terminated | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib | November 2005 | October 2006 | |
| NCT01303159 | Terminated | N/A | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer | March 2010 | January 13, 2014 |
| NCT02393248 | Terminated | Phase 1/Phase 2 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | February 27, 2015 | December 17, 2021 |
| NCT02374489 | Terminated | Phase 2 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | March 2015 | January 2018 |
| NCT01434459 | Terminated | Phase 1 | Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin | September 2011 | September 2014 |
| NCT01721174 | Terminated | N/A | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | November 2012 | December 2017 |
| NCT04648319 | Terminated | Phase 2 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | April 15, 2021 | January 17, 2022 |
| NCT00708877 | Terminated | N/A | Liver Transplantation for Cholangiocarcinoma | March 2007 | July 2011 |
| NCT00426829 | Terminated | Phase 1 | Proton Therapy and Bevacizumab for Primary Liver Tumors | May 2007 | November 2009 |
| NCT03144661 | Terminated | Phase 1 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | May 25, 2017 | June 10, 2020 |
| NCT04644315 | Terminated | Phase 2 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | May 24, 2021 | May 16, 2022 |
| NCT00907413 | Terminated | Phase 3 | Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma | May 2010 | June 2011 |
| NCT01151761 | Terminated | Phase 2 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | January 2011 | July 2012 |
| NCT04566133 | Terminated | Phase 2 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | February 15, 2022 | December 31, 2022 |
| NCT02012231 | Terminated | Phase 1 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | February 2014 | June 2015 |
| NCT04683939 | Terminated | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | January 18, 2022 | July 24, 2023 |
| NCT00540735 | Terminated | Phase 3 | Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas | April 2008 | November 2009 |
| NCT04066491 | Terminated | Phase 2/Phase 3 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | September 20, 2019 | November 10, 2022 |
| NCT00630890 | Terminated | Phase 1 | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) | October 2007 | December 2008 |
| NCT04076761 | Terminated | Phase 2 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma | December 11, 2019 | September 30, 2022 |
| NCT04077372 | Terminated | N/A | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | September 16, 2019 | October 11, 2020 |
| NCT04099888 | Terminated | Phase 2 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer | May 23, 2019 | May 6, 2022 |
| NCT04727541 | Terminated | Phase 2 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer | July 8, 2021 | January 5, 2022 |
| NCT01442324 | Unknown status | N/A | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | February 2011 | |
| NCT04866836 | Unknown status | Phase 2 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors | October 1, 2020 | October 1, 2022 |
| NCT01642875 | Unknown status | Phase 4 | Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy | November 2016 | December 2020 |
| NCT01525719 | Unknown status | Phase 2 | Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma | January 2012 | June 2014 |
| NCT03734926 | Unknown status | Phase 1 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | November 13, 2018 | October 31, 2021 |
| NCT03603834 | Unknown status | Phase 2 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | September 19, 2018 | December 2023 |
| NCT03774589 | Unknown status | N/A | Bilioenteric Anastomosis by Magnetic Compressive Technique | February 1, 2019 | January 31, 2022 |
| NCT03779035 | Unknown status | Phase 3 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | December 15, 2018 | December 31, 2023 |
| NCT03792048 | Unknown status | N/A | Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure | February 1, 2019 | January 31, 2022 |
| NCT03499782 | Unknown status | Precise Treatment System of Biliary Malignancies Based on Special Disease Database | May 25, 2018 | December 31, 2021 | |
| NCT00973713 | Unknown status | Phase 2 | Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol | September 2009 | March 2012 |
| NCT03896958 | Unknown status | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | March 21, 2019 | March 12, 2024 | |
| NCT03166436 | Unknown status | N/A | RFA for Malignant Biliary Obstruction | June 8, 2017 | May 8, 2020 |
| NCT03943043 | Unknown status | Phase 1/Phase 2 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | July 21, 2017 | May 1, 2021 |
| NCT03951324 | Unknown status | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study | May 10, 2019 | December 31, 2019 | |
| NCT00653978 | Unknown status | Phase 3 | Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures | May 2008 | December 2011 |
| NCT01522573 | Unknown status | T-EUS for Gastrointestinal Disorders: A Multicenter Registry | November 2011 | December 30, 2018 | |
| NCT03140007 | Unknown status | N/A | Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic . | June 15, 2017 | June 15, 2018 |
| NCT03102268 | Unknown status | ncRNAs in Exosomes of Cholangiocarcinoma | May 1, 2017 | March 31, 2020 | |
| NCT03042182 | Unknown status | Phase 1/Phase 2 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma | February 20, 2017 | April 20, 2020 |
| NCT02665494 | Unknown status | Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors | January 2016 | December 2019 | |
| NCT04243057 | Unknown status | Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study | August 30, 2019 | September 30, 2022 | |
| NCT02659852 | Unknown status | N/A | A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction | January 2016 | January 2020 |
| NCT02607826 | Unknown status | N/A | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors | November 2016 | March 2019 |
| NCT02582541 | Unknown status | N/A | Endoscopic Biliary RFA of Malignant Bile Duct Obstruction | February 2014 | November 2018 |
| NCT02548195 | Unknown status | Phase 3 | Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | July 2015 | December 2018 |
| NCT02528526 | Unknown status | Phase 1/Phase 2 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm | February 2014 | December 2016 |
| NCT04415190 | Unknown status | the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients | June 1, 2020 | December 31, 2020 | |
| NCT02436564 | Unknown status | In Vitro Models of Liver and Pancreatic Cancer | July 2015 | ||
| NCT01739465 | Unknown status | Phase 2/Phase 3 | Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma | November 2012 | |
| NCT01439698 | Unknown status | Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry | September 2011 | December 30, 2018 | |
| NCT00290316 | Unknown status | Phase 2 | Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver | July 2004 | January 2006 |
| NCT02162914 | Unknown status | Phase 2 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma | March 14, 2014 | December 2020 |
| NCT01438385 | Unknown status | Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders | July 2011 | December 30, 2017 | |
| NCT01920503 | Unknown status | International Registry on Cholangiocarcinoma Treatment | July 2013 | August 2020 | |
| NCT04633382 | Unknown status | N/A | ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY | January 1, 2021 | January 1, 2022 |
| NCT04637048 | Unknown status | Observational Study on Patients With Hepatobiliary Tumors | February 16, 2017 | December 1, 2023 | |
| NCT01868490 | Unknown status | Phase 1/Phase 2 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells | April 17, 2009 | May 30, 2020 |
| NCT00797121 | Unknown status | Phase 4 | Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma | May 2008 | May 2013 |
| NCT01755013 | Unknown status | Phase 2/Phase 3 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | February 2012 | March 22, 2018 |
| NCT04764084 | Unknown status | Phase 1 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | April 1, 2021 | February 28, 2023 |
| NCT00160836 | Unknown status | Phase 1 | Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter | October 2004 | |
| NCT01439685 | Withdrawn | Comparison of Biliary Stenting Alone vs. Stenting With Photodynamic Therapy (PDT) During ERCP | July 2011 | May 2014 | |
| NCT04480190 | Withdrawn | Phase 1 | Neoadjuvant Therapy in Biliary Adenocarcinoma | February 4, 2021 | April 4, 2022 |
| NCT02174575 | Withdrawn | Phase 4 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | July 2014 | May 2023 |
| NCT00713687 | Withdrawn | Phase 2 | Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma | August 2008 | December 2011 |
| NCT01501604 | Withdrawn | Phase 2 | BKM120 in Cancers With PIK3CA Activating Mutations | January 2012 | August 2013 |
| NCT04717687 | Withdrawn | N/A | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma | May 1, 2021 | June 1, 2022 |
| NCT01875549 | Withdrawn | N/A | Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent | May 2013 | May 2016 |
| NCT04584775 | Withdrawn | N/A | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | February 2021 | July 2022 |
| NCT03563352 | Withdrawn | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | August 30, 2018 | September 24, 2020 | |
| NCT04895046 | Withdrawn | Phase 2 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | October 11, 2021 | September 2023 |
| NCT00604266 | Withdrawn | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study | August 2007 | August 2008 | |
| NCT02106871 | Withdrawn | Phase 1 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer | April 2014 | June 2017 |
| NCT05510427 | Withdrawn | Phase 1 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | August 7, 2023 | August 7, 2023 |
- Disase is a (Disease Ontology)
- DOID:4896
- Cross Reference ID (Disease Ontology)
- ICD10CM:C22.1
- Cross Reference ID (Disease Ontology)
- ICDO:8160/3
- Cross Reference ID (Disease Ontology)
- MESH:D018281
- Cross Reference ID (Disease Ontology)
- NCI:C4436
- Cross Reference ID (Disease Ontology)
- NCI:C8265
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:70179006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206698
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0280725
- Exact Synonym (Disease Ontology)
- adult primary Cholangiocarcinoma
- Exact Synonym (Disease Ontology)
- adult primary cholangiocellular carcinoma
- Exact Synonym (Disease Ontology)
- cholangiosarcoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030153
- OrphaNumber from OrphaNet (Orphanet)
- 70567
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018281